Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 4.41% and Operating profit at -4.32% over the last 5 years
2
The company declared positive results in Mar'25 after negative results in Dec'24
3
With ROE of 7.38%, it has a fair valuation with a 0.74 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,202 Million (Small Cap)
10.00
NA
1.65%
-0.62
7.38%
0.74
Revenue and Profits:
Net Sales:
113 Million
(Quarterly Results - Jun 2025)
Net Profit:
36 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.18%
0%
-13.18%
6 Months
-4.14%
0%
-4.14%
1 Year
44.37%
0%
44.37%
2 Years
-9.06%
0%
-9.06%
3 Years
10.59%
0%
10.59%
4 Years
-37.89%
0%
-37.89%
5 Years
-39.41%
0%
-39.41%
Nanjing Vishee Medical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.41%
EBIT Growth (5y)
-4.32%
EBIT to Interest (avg)
92.07
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.62
Sales to Capital Employed (avg)
0.26
Tax Ratio
11.10%
Dividend Payout Ratio
74.87%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
65.26%
ROE (avg)
8.58%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
0.74
EV to EBIT
2.06
EV to EBITDA
1.60
EV to Capital Employed
0.32
EV to Sales
0.47
PEG Ratio
3.36
Dividend Yield
1.65%
ROCE (Latest)
15.39%
ROE (Latest)
7.38%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
113.00
102.60
10.14%
Operating Profit (PBDIT) excl Other Income
38.20
25.50
49.80%
Interest
0.40
0.30
33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
36.10
27.90
29.39%
Operating Profit Margin (Excl OI)
267.50%
189.70%
7.78%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 10.14% vs -16.38% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 29.39% vs -31.11% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
394.50
456.50
-13.58%
Operating Profit (PBDIT) excl Other Income
105.70
136.60
-22.62%
Interest
1.30
1.30
Exceptional Items
2.40
-1.00
340.00%
Consolidate Net Profit
102.00
136.30
-25.17%
Operating Profit Margin (Excl OI)
208.70%
251.00%
-4.23%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -13.58% vs 43.73% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -25.17% vs 45.31% in Dec 2023
About Nanjing Vishee Medical Technology Co., Ltd. 
Nanjing Vishee Medical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






